SEC Tracker
Get the app

Tempest Therapeutics TPST

Tempest Therapeutics reports $26,262 net loss

Proxy statement

Form
DEF 14A
Filed
Importance
Routine
  1. Net loss of $26,262 for the year ended Dec 31, 2025
  2. Annual Meeting scheduled for Nov 9, 2026
  3. Election of two board nominees
  4. Ratification of Ernst & Young LLP as accounting firm

Written from the DEF 14A on EDGAR. Check the filing before you rely on it.

Open in the appGet the appView on EDGAR

Get an email when Tempest Therapeutics files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.

  1. ProMIS Neurosciences PMN public float $30M, Jun 30, 2025
  2. Provectus Biopharmaceuticals PVCT public float $31M, Jun 30, 2025
  3. Cumberland Pharmaceuticals CPIX public float $29M, Jun 30, 2025
  4. Rockwell Medical RMTI public float $29M, Jun 30, 2025
  5. Champions Oncology CSBR public float $29M, Oct 31, 2025